CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：17
|
作者：
Capi, Matilde [1 ]
De Angelis, Valerio [2 ]
De Bernardini, Donatella [1 ]
De Luca, Ottavia [3 ]
Cipolla, Fabiola [2 ]
Lionetto, Luana [1 ]
Simmaco, Maurizio [1 ,3 ,4 ]
Martelletti, Paolo [2 ]
机构：
[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy
[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy
[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy
[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期
关键词：
migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;
D O I：
10.3390/jcm10071429
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.
引用
收藏
页数：17
相关论文
共 50 条
  • [1] Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370.
    Goldstein, DJ
    Roon, KI
    Offen, WW
    Phebus, LA
    Johnson, KW
    Schaus, JM
    VanLaar, T
    Ferrari, MD
    CEPHALALGIA, 1999, 19 (04) : 318 - 318
  • [2] 5-HT1F receptor agonists in acute migraine treatment:: a hypothesis
    Ramadan, NM
    Skljarevski, V
    Phebus, LA
    Johnson, KW
    CEPHALALGIA, 2003, 23 (08) : 776 - 785
  • [3] 5-HT1F Receptor Agonists: A New Treatment Option for Migraine Attacks?
    Neeb, Lars
    Meents, Jannis
    Reuter, Uwe
    NEUROTHERAPEUTICS, 2010, 7 (02) : 176 - 182
  • [4] 5-HT1F receptor agonists: A new treatment option for migraine attacks?
    Lars Neeb
    Jannis Meents
    Uwe Reuter
    Neurotherapeutics, 2010, 7 : 176 - 182
  • [5] The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
    Reuter, Uwe
    Israel, Heike
    Neeb, Lars
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 46 - 54
  • [6] LASMIDITAN HYDROCHLORIDE 5-HT1F Receptor Agonist Antimigraine Drug
    Reuter, U.
    Neeb, L.
    DRUGS OF THE FUTURE, 2012, 37 (10) : 709 - 716
  • [7] CGRP receptor antagonists for the treatment of migraine
    Bell, Ian M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [8] COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy
    Pilgrim, A. J.
    Dussault, B.
    Rupniak, N. M. J.
    White, J.
    Mazur, D.
    DiSanto, A. R.
    CEPHALALGIA, 2009, 29 : 24 - 25
  • [9] The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside
    Mitsikostas, Dimos D.
    Waeber, Christian
    Sanchez-del-Rio, Margarita
    Raffaelli, Bianca
    Ashina, Hakan
    van den Brink, Antoinette Maassen
    Andreou, Anna
    Pozo-Rosich, Patricia
    Rapoport, Alan
    Ashina, Messoud
    Moskowitz, Michael A.
    NATURE REVIEWS NEUROLOGY, 2023, 19 (08) : 489 - 505
  • [10] The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside
    Dimos D. Mitsikostas
    Christian Waeber
    Margarita Sanchez-del-Rio
    Bianca Raffaelli
    Håkan Ashina
    Antoinette Maassen van den Brink
    Anna Andreou
    Patricia Pozo-Rosich
    Alan Rapoport
    Messoud Ashina
    Michael A. Moskowitz
    Nature Reviews Neurology, 2023, 19 : 489 - 505
12345